Treated groups with L-carnitine showed upregulation of Nrf2/Keap1/NQO1 expression which proposed that Nrf2/Keap1/NQO1 activation is implicated in the therapeutic effect of L-carnitine against acute lung injury. The gene discussed is NFE2L2; the disease is injury.